When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Harrow just met that criteria with a new score of 87.
Hone Your Stock-Picking Skills By Focusing On These Factors
This unique rating identifies technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they launch their biggest runs.
Harrow is now considered extended and out of buy range after clearing a 20.31 buy point in a third-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Harrow reported 0% earnings growth in its most recent report, while sales growth came in at 84%. Keep an eye out for the company's next round of numbers on or around May 19.
The company holds the No. 46 rank among its peers in the Medical-Biomed/Biotech industry group. GeneDx Holdings, ADMA Biologics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
